SHANGHAI, China I July 7, 2017 I CARsgen Therapeutics (CARsgen), a global pioneer focused on developing novel chimeric antigen receptor T-cell (CAR-T cell) therapies for solid tumors, today announced its next-generation safety switch technology was published in the latest issue of the journal Molecular Therapy, with title of “A fusion receptor as a safety switch, detection and purification biomarker for adoptive transferred T-cells”. Its strategic partners Shanghai Cancer Institute and Shanghai Renji Hospital co-authored this work.
“Safety switch technology is critical to the adoptive T cell immunotherapy, particularly CAR-T cell therapy. It can be used to control cell survival, to reduce cell toxicity, and to improve safety profile.” Dr. Zonghai Li, President & CEO of CARsgen Therapeutics, said, “Our next-generation safety switch, fusion receptor FR806, has shown the promising activity in the preclinical studies. It provides us an effective tool to reduce the risk of SAE found in the CAR-T therapy. We are happy to become one of very few companies who own IP of next-generation safety switch and technical know-how. This cutting-edge technology will be further investigated in CAR-T pipeline development and future clinical trials.”
About CARsgen Therapeutics
CARsgen Therapeutics is a rapidly growing bio-tech start-up with the original CAR-T therapy discovery expertise, competitive GMP manufacturing capability, and global clinical development experience. CARsgen commits to delivering the most advanced yet affordable cell therapies to patients with unmet medical needs. With broad discovery pipeline across solid tumor and hematology malignancies, CARsgen proceeds the clinical development with a clear focus in CAR-T therapy for solid tumors. Four of its pioneering CAR-T cell therapies, anti-GPC3 CAR-T for hepatocellular carcinoma (HCC), anti-GPC3 CAR-T for squamous lung cancer (SLC), cancer-specific anti-EGFR CAR-T for glioblastoma multiforme (GBM) and first-in-class anti-Claudin18.2-CAR-T for gastric and pancreatic cancer have all entered early clinical development. For more information, please visit the website: www.carsgen.com
SOURCE: CARsgen Therapeutics
Post Views: 24
SHANGHAI, China I July 7, 2017 I CARsgen Therapeutics (CARsgen), a global pioneer focused on developing novel chimeric antigen receptor T-cell (CAR-T cell) therapies for solid tumors, today announced its next-generation safety switch technology was published in the latest issue of the journal Molecular Therapy, with title of “A fusion receptor as a safety switch, detection and purification biomarker for adoptive transferred T-cells”. Its strategic partners Shanghai Cancer Institute and Shanghai Renji Hospital co-authored this work.
“Safety switch technology is critical to the adoptive T cell immunotherapy, particularly CAR-T cell therapy. It can be used to control cell survival, to reduce cell toxicity, and to improve safety profile.” Dr. Zonghai Li, President & CEO of CARsgen Therapeutics, said, “Our next-generation safety switch, fusion receptor FR806, has shown the promising activity in the preclinical studies. It provides us an effective tool to reduce the risk of SAE found in the CAR-T therapy. We are happy to become one of very few companies who own IP of next-generation safety switch and technical know-how. This cutting-edge technology will be further investigated in CAR-T pipeline development and future clinical trials.”
About CARsgen Therapeutics
CARsgen Therapeutics is a rapidly growing bio-tech start-up with the original CAR-T therapy discovery expertise, competitive GMP manufacturing capability, and global clinical development experience. CARsgen commits to delivering the most advanced yet affordable cell therapies to patients with unmet medical needs. With broad discovery pipeline across solid tumor and hematology malignancies, CARsgen proceeds the clinical development with a clear focus in CAR-T therapy for solid tumors. Four of its pioneering CAR-T cell therapies, anti-GPC3 CAR-T for hepatocellular carcinoma (HCC), anti-GPC3 CAR-T for squamous lung cancer (SLC), cancer-specific anti-EGFR CAR-T for glioblastoma multiforme (GBM) and first-in-class anti-Claudin18.2-CAR-T for gastric and pancreatic cancer have all entered early clinical development. For more information, please visit the website: www.carsgen.com
SOURCE: CARsgen Therapeutics
Post Views: 24
